What Organon Canada does

Organon Canada Inc. is the Canadian subsidiary of Organon (NYSE: OGN), a global healthcare company headquartered in Kirkland, Canada, with 101-250 employees. Founded in 2021 as part of Organon's spinoff from Merck & Co., the company commercializes a portfolio of 60+ pharmaceutical medicines in Canada spanning three focus areas: Women's Health (covering reproductive health needs across a woman's lifetime), Biosimilars (offering cost-efficient biologic alternatives across multiple therapeutic areas), and General Medicines (respiratory, cardiovascular, and dermatology products). The subsidiary operates as part of Organon's broader footprint serving more than 140 markets globally.

The company distributes pharmaceutical products through traditional healthcare channels including retail and hospital pharmacies and direct sales to hospitals and healthcare providers. Its biosimilars portfolio was recently expanded to eight products across five therapeutic areas following the June 2026 launch of BILDYOS® (a denosumab biosimilar to Amgen's PROLIA, indicated for osteoporosis) and TUZEMTY® (a denosumab biosimilar to Amgen's XGEVA, indicated for bone events associated with cancer). These launches were enabled by a 2022 license and supply agreement with Shanghai Henlius Biotech, under which Organon holds exclusive global commercialization rights outside China.

Organon Canada's revenue model is prescription pharmaceutical product sales, with pricing not publicly disclosed and reimbursement typically handled through provincial drug benefit plans, private insurance, or out-of-pocket patient payment. The go-to-market motion is enterprise field sales, with ongoing healthcare professional engagement, events, and PR-driven communications through the corporate website and LinkedIn. The parent Organon group, including its Canadian subsidiary, holds strong brand recognition globally, has a foundational proprietary portfolio in reproductive health, and possesses exclusive commercialization rights to its biosimilar pipeline derived from the Henlius partnership.

Name

Organon Canada

Legal name

Organon Canada Inc.

Website

https://organon.ca

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Organon Canada Inc. is the Canadian subsidiary of Organon (NYSE: OGN), commercializing over 60 pharmaceutical products across women's health, biosimilars, and general medicines (respiratory, cardiovascular, dermatology) through pharmacies, hospitals, and healthcare providers in Canada.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Biologics & Biosimilars Distributors (HLAIAJAH), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Women's health pharmaceuticals
• Biosimilar medicines
• Reproductive health products
• Cardiovascular medications
• Dermatology pharmaceuticals

Headquarters

HQ city

Kirkland

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Marketing or Sales, Personnel, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Organon Canada generates revenue through the sale of prescription pharmaceutical products including branded medicines, biosimilars, and general medicines across therapeutic areas including reproductive health, immunology, cardiovascular disease, dermatology, allergies and asthma.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Organon Canada commercializes a portfolio of branded pharmaceutical products, biosimilars, and general medicines across therapeutic areas including women's reproductive health, immunology, cardiovascular disease, dermatology, allergies, and asthma. The company distributes these prescription medicines through Canadian pharmacies, hospitals, and healthcare providers, and recently expanded its biosimilars portfolio to eight products across five therapeutic areas with the launch of denosumab biosimilars BILDYOS® and TUZEMTY®.

Product overview

Organon Canada offers a portfolio of pharmaceutical products organized across three main areas: Women's Health (addressing reproductive health needs throughout a woman's lifetime), Biosimilars (offering treatment options across multiple therapeutic areas including osteoporosis and cancer-related bone conditions), and General Medicines (maintaining access to medications in respiratory, cardiovascular, and dermatology). The company recently launched two denosumab biosimilars — BILDYOS® (biosimilar to PROLIA) and TUZEMTY® (biosimilar to XGEVA) — expanding the Canadian biosimilars portfolio to eight products spanning five therapeutic areas. The overall portfolio builds upon more than 60 medicines and products across reproductive health, immunology, cardiovascular disease, dermatology, allergies and asthma.

Differentiator

Problem solved

Functional benefit

Products and services

• BILDYOS® (denosumab injection)
• TUZEMTY® (denosumab injection)

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Shanghai Henlius BiotechcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Organon Canada and Shanghai Henlius Biotech entered a license and supply agreement in 2022. Under this agreement, Organon holds exclusive commercialization rights globally except in China. The partnership led to the launch of two denosumab biosimilars—BILDYOS® and TUZEMTY®—which are biosimilar alternatives to Amgen's PROLIA and XGEVA respectively, for the treatment of osteoporosis and bone events associated with cancer. This partnership expanded Organon's Canadian biosimilars portfolio to eight products spanning five therapeutic areas.

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Amgen Canada: Amgen Canada is the originator of PROLIA and XGEVA (denosumab), the branded biologics that Organon Canada's BILDYOS and TUZEMTY biosimilars directly compete against. Both companies sell into the same osteoporosis and bone-metastasis markets via similar pharmacy and hospital channels.
• Apotex Inc. Apotex is one of Canada's largest generic pharmaceutical manufacturers, with a growing biosimilars business and significant women's health and hospital product presence. It competes with Organon Canada across multiple institutional formularies.
• Teva Canada: Teva Canada is a leading Canadian generic and biosimilar manufacturer with a broad portfolio competing across immunology, oncology-supportive care, and women's health, mirroring Organon Canada's diversified branded-plus-biosimilar positioning.
• Sandoz Canada: Sandoz is the world's largest biosimilars company and a direct competitor in the Canadian biosimilars market, with multiple approved biosimilars across the same therapeutic areas where Organon Canada competes. Both rely on wholesaler and hospital distribution channels for biologic uptake.

Emerging players

• Alvotech: Alvotech is a global biosimilars developer with multiple molecules advancing through Canadian and global regulatory approval, positioned to compete with Organon Canada's denosumab and other biosimilars on cost and supply reliability.
• Samsung Bioepis (Canada): Samsung Bioepis is one of the leading global biosimilar developers with multiple approved products in Canada and additional molecules in development. It is an emerging direct competitor to Organon Canada's biosimilars franchise.

Broad incumbents

• Pfizer Canada: Pfizer Canada is a large incumbent pharmaceutical company with significant women's health, immunology, and biosimilars exposure (e.g., via Hospira heritage). It competes broadly with Organon Canada's portfolio across prescription and institutional channels.
• Bayer Canada: Bayer Canada has a meaningful women's health franchise (contraception, menopause, gynecology) and competes directly with Organon's women's health priority, in addition to cardiovascular and respiratory products.
• Merck Canada: Merck Canada is the originator parent from which Organon was spun off in 2021. It remains a major incumbent in immunology, women's health (via remaining fertility portfolio), and general medicines, sharing therapeutic-area overlap with Organon Canada.

Regional players

• Biogen Canada: Biogen Canada operates in neuroscience and biosimilars in Canada, with a biosimilars partnership (Bio-Thera, Samsung Bioepis) overlapping with Organon Canada's therapeutic-area focus in immunology and bone-health biologics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/organoncanada
• Xx.com/organoncanada

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organon Canada